The incidence of severe infections caused by extended-spectrum β-lactamase (ESBL)--producing *Enterobacterales* (E) is a rising concern worldwide, owing to the successful dissemination of these species in both the community and health care--associated ecosystem \[[@CIT0001]\]. This situation has led to a dramatic increase in the use of carbapenems in high-prevalence countries, which is suspected to contribute to the ongoing pandemic of carbapenemase-producing *Enterobacterales*. Therefore, alternative treatment options and carbapenem-sparing regimens for patients with serious infections caused by ESBL-E are urgently needed \[[@CIT0004]\].

Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-lactamase inhibitor (BLBLI) combination that has shown potent activity against gram-negative bacteria \[[@CIT0005]\]. It is the combination of a novel cephalosporin, structurally like ceftazidime, with a well-known β-lactamase inhibitor. Similar to ceftazidime and other expanded-spectrum cephalosporins, ceftolozane is not stable when combined with ESBL. For this reason, a formulation for clinical use has been developed in combination with tazobactam, a mechanism-based β-lactamase inhibitor that extends the activity of ceftolozane against many ESBL-E \[[@CIT0006]\].

Pivotal clinical trials of C/T have demonstrated its efficacy and safety for the treatment of ESBL infections \[[@CIT0007], [@CIT0008]\] and clinical experiences with C/T are accumulating and expanding. However, these studies are almost completely focused on treatment of *Pseudomonas aeruginosa* infections \[[@CIT0009]\]. Information regarding its real-life use, efficacy, and tolerability against ESBL-E in daily clinical practice is limited. Here we report a clinical multicenter experience with C/T to treat serious infections due to ESBL-E since its approval in Italy.

METHODS {#s1}
=======

Study Setting and Design {#s2}
------------------------

This was a multicenter retrospective study in which we included all adult patients treated with C/T (for at least 96 hours) for any confirmed infection produced by ESBL-producing *Enterobacterales* between June 2016 and June 2019 (36-month period) in 12 hospitals in Italy. The Internal Review Board of Medical Area (DAME) of the coordinating center (Azienda Ospedaliera Universitaria Integrata di Udine, Udine, Italy) approved this study. Because of its retrospective nature, informed consent was considered unnecessary.

Cases were eligible for the cohort study if the patient (i) was aged ≥18 years, (ii) received ≥96 hours of C/T (with or without other antibiotics), and (iii) had a culture-confirmed ESBL-E infection.

Data Collection {#s3}
---------------

Patients' medical records were retrospectively reviewed, and data were collected using a pre-established form. The following data were recorded: age and sex, underlying diseases according to Charlson comorbidity index, type of infection, presence of sepsis or septic shock at the time of the infection, susceptibility pattern of ESBL-E isolates, date of start and end of C/T therapy, source control of infection, when applicable, other antibiotics administered before, concomitant to, and after C/T therapy, reasons for C/T use, dosage(s) of C/T and length of therapy, adverse events (AEs), clinical outcome, and recurrence of infection.

Definitions {#s4}
-----------

Chronic renal disease was defined as the need for hemodialysis or the presence of renal impairment (serum creatinine \>1.5 mg/dL) at the time of hospital admission. Diagnosis and classification of infections were defined according to the criteria of the US Centers for Disease Control and Prevention (CDC) \[[@CIT0012]\]. Sepsis and septic shock were defined according to standard international criteria \[[@CIT0013]\]. Source control of infection was considered adequate when any additional measures were taken to control the focus of the infection in the 48 hours after infection onset (ie, removal of urinary catheter or intravascular catheter, as well as surgical or radiological drainage of collection).

An infection was considered "life-threatening" when a patient (i) received C/T as rescue therapy because of clinical failure of a previous antibiotic regimen, (ii) had septic shock at the time of ESBL-E infection, or (iii) required intensive care unit (ICU) admission at the time of ESBL-E infection. Recurrence was considered to have occurred if the infection reappeared after antibiotic discontinuation.

Antibiotic Therapy {#s5}
------------------

Indications for C/T and dosage, type of infusion, and duration were established by infectious diseases specialists in each participating center, based on knowledge of previous colonization, clinical presentation, and local guidelines. C/T was dosed either as approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as an intravenous (i.v.) dose of 1.5 g every 8 h (q8h; standard dosage) or as supported by recent data in patients with nosocomial pneumonia \[[@CIT0014]\] as an i.v. dose of 3 g q8h (off-label dosage at time of treatment); moreover, dosages were adjusted according to creatinine clearance. Dose adjustment was required only for patients with moderate renal dysfunction (creatinine clearance \< 50 mL/min). In patients receiving continuous renal replacement therapy (CRRT), C/T was administered at 1.5 g q8h, as suggested by pharmacokinetic studies \[[@CIT0015], [@CIT0016]\]. AEs were classified according to World Health Organization (WHO) definitions \[[@CIT0017]\].

Depending on the number of drugs used, treatment regimens were classified either as monotherapy or combination therapy. Initial antibiotic therapy, defined as empirical antimicrobial chemotherapy implemented within 24 hours after the onset of infection, was assessed, along with definitive antibiotic therapy, defined as antimicrobial treatment based on in vitro ESBL-E isolate susceptibilities. Drugs in definitive therapy must have been administered for at least 50% of the total duration of therapy (except for patients who died while on definitive therapy, who were included if they received at least 1 complete day of therapy). Time to initial definitive therapy was the period between the infection onset and initial definitive therapy.

Definition of Patient Outcome {#s6}
-----------------------------

Patient outcome was assessed as success or failure at the end of the follow-up period, which finished at the end of August 2019. A successful clinical outcome was defined as complete resolution of clinical signs and symptoms related to ESBL-E infection and lack of microbiological evidence of infection. Clinical failure was defined as either lack of clinical response and/or recurrence and/or attributable mortality due to ESBL-E infection. Specifically, clinical failure was defined as a composite of the following: (i) 30-day mortality; (ii) ongoing fever after 5 days of therapy; (iii) persistence of leukocytosis after 5 days of therapy; (iv) presence, after 5 days of therapy, of clinical signs of infection that could not be attributed to causes other than ESBL-E infection. Clinical success was defined also as absence of clinical failure.

Microbiological Methods {#s7}
-----------------------

All ESBL-E isolates were processed at each participating center according to their own practice. In all cases, antibiotic susceptibility was determined by the Vitek 2 (Biomerieux, France) automatic method. ESBL-producing strains were phenotypically identified from baseline specimens using the following criteria: minimum inhibitory concentration (MIC) \>1 mg/L for a third-generation cephalosporin (ceftazidime and/or cefotaxime or ceftriaxone); phenotypic ESBL confirmation for *Enterobacterales* in which chromosomal AmpC is uncommon (*E. coli*, *Klebsiella* spp., *Proteus* spp.) with an MIC decrease of \>3 dilutions when combined with clavulanic acid; phenotypic ESBL confirmation for *Enterobacterales* in which chromosomal AmpC β-lactamase is common (*Enterobacter* spp., *Citrobacter* spp., *Serratia* spp., *Providencia* spp.) using an MIC of cefepime with a decrease of \>3 dilutions when cefepime is combined with clavulanic acid. However, ESBL detection in each center was confirmed as previously reported \[[@CIT0018]\].

Susceptibility of bacteria to C/T was determined by the Etest (Liofilmchem, Roseto degli Abruzzi, Italy), and the results were interpreted according to the breakpoints proposed by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) \[[@CIT0019]\].

Statistical Analysis {#s8}
--------------------

The primary end point was to identify predictors of clinical failure of C/T therapy.

Continuous variables were compared using the Student *t* test and Mann-Whitney *U* test for normally and non--normally distributed variables, respectively. The χ ^2^ test or Fisher exact test was used to compare categorical variables. All pretreatment variables identified during univariate analysis were tested using logistic regression analysis to identify risk factors associated with clinical failure. In a multivariate analysis, the model was tested using a backward stepwise selection and *P* \< .05 for all variables in order to determine the effects of all anamnestic, clinical, and therapeutic variables on clinical success or failure of C/T therapy. Empiric and definitive therapy were adjusted for confounders (definitive and empiric regimens, respectively). All tests of statistical significance were 2-tailed. Differences were considered statistically significant at a *P* value of \<.05. Statistical analysis was performed with the software package PASW Statistics, version 20.0 (SPSS Inc., Chicago, IL, USA).

RESULTS {#s9}
=======

A total of 153 patients were included during the study period, with a median number (interquartile range \[IQR\]) of 10 (2--28) enrolled cases among 12 centers. The baseline characteristics of study population are shown in [Table 1](#T1){ref-type="table"}. Overall, the median age (IQR) was 69 (48--77) years, 82 (53.6%) patients were male, and the mean ± SD Charlson comorbidity index score was 4.9 ± 3.6. The most frequent source of infection was hospital-acquired pneumonia (HAP) in 46 patients (30%, including 20 patients with ventilator-associated pneumonia), followed by complicated urinary tract infections (cUTIs; 22.2% of cases, 34/153), acute bacterial skin and skin structure infections (ABSSSIs; 16.3%), and complicated intra-abdominal infections (cIAIs; 16.3%, 25/153 each). Concomitant bloodstream infection was confirmed in 30.7% (47/153 patients).

###### 

Baseline Demographics and Clinical Characteristics of 153 Patients Included in the Efficacy Population Analysis

  Variable                                                              n = 153 (%)^a^
  --------------------------------------------------------------------- ----------------
  Age, median (IQR), y                                                  69 (48--77)
  Male sex                                                              82 (53.6)
  Community-acquired infection                                          10 (6.5)
  Hospital-acquired infection                                           143 (93.5)
  Ward                                                                  
   Medical                                                              98 (64)
   Surgical                                                             25 (16.4)
   ICU                                                                  30 (19.6)
   Charlson comorbidity index, mean ± SD                                4.9 ± 3.6
  Underlying diseases                                                   
   Cardiac disease                                                      56 (36.6)
   Neurological disease                                                 53 (34.6)
   Chronic renal disease                                                51 (33.3)
   Diabetes mellitus                                                    42 (27.4)
   Gastrointestinal disease                                             41 (26.7)
   Solid-organ tumor                                                    37 (24.1)
   Solid-organ transplant                                               19 (12.4)
   Hematological malignancy                                             20 (13)
   COPD                                                                 35 (22.8)
   Liver disease                                                        22 (14.3)
  Other predisposing conditions^b^                                      
   Corticosteroids                                                      52 (33.9)
   Other immunosuppressive therapy                                      29 (18.9)
   Chemotherapy                                                         17 (11.1)
   Neutropenia^c^                                                       15 (9.8)
  Invasive procedures                                                   
   Central venous catheter                                              76 (49.7)
   Urinary catheter                                                     111 (72.5)
   Previous surgery^b^                                                  58 (37.9)
   Mechanical ventilation/NIV                                           28 (18.3)
   Percutaneous endoscopic gastrostomy                                  2 (1.3)
   Intermittent hemodialysis                                            25 (16.3)
   CRRT                                                                 18 (11.7)
   Previous ESBL-E colonization^b^                                      50 (32.6)
  Severity of clinical presentation                                     
   No sepsis                                                            52 (33.9)
   Sepsis                                                               59 (38.6)
   Septic shock                                                         42 (27.5)
  ICU admission due to ESBL-E infection                                 74 (48.3)
  Type of infection                                                     
   Nosocomial pneumonia^e^                                              46 (30)
   ABSSSI                                                               25 (16.3)
   cUTI                                                                 34 (22.2)
   cIAI                                                                 25 (16.3)
   Bone infection                                                       5 (3.2)
   Primary bacteremia                                                   16 (10.4)
   Other infections^d^                                                  2 (1.3)
  Concomitant ESBL-E bacteremia                                         47 (30.7)
  Life-threatening infection                                            91 (59.4)
  Polymicrobial infection                                               31 (20.2)
  Antibiotics before C/T treatment                                      
   Received antibiotics before C/T for current infection                52 (33.9)
   No. of antibiotics received, median (range)                          1 (1--3)
   Days of antibiotic therapy, median (range)                           6 (3--14)
  C/T treatment                                                         
   Empiric treatment                                                    46 (30)
   Combination therapy                                                  26 (16.9)
   Time from infection onset to C/T administration, median (IQR), d     6 (3--15)
   Days of treatment, median (range)                                    14 (8--25)
   Extended infusion                                                    34 (22.2)
   Continuous infusion                                                  11 (7.2)
   Intermittent infusion                                                108 (70.6)
   Standard dosage (or adjusted according to creatinine clearance)^f^   115 (75)
   Off-label dosage                                                     38 (25)
   Adequate source control of infection                                 47/57 (82.4)
  Successful clinical outcome                                           128 (83.7)
  30-d mortality                                                        15 (9.8)

Abbreviations: ABSSSI, acute bacterial skin and skin-structure infection; C/T, ceftolozane/tazobactam; cIAI, complicated intra-abdominal infection; COPD, chronic obstructive pulmonary disease; CRRT, continuous renal replacement therapy; cUTI, complicated urinary tract infection; ICU, intensive care unit; ICU, intensive care unit; IQR, interquartile range; NIV, noninvasive ventilation.

^a^Data are presented as No. (%) unless otherwise stated.

^b^Within the previous 30 days.

^c^Absolute neutrophil count \<500/mm^3^.

^d^Other infections include central venous catheter--related bacteremia (n = 1) and community-acquired pneumonia (n = 1).

^e^Thirty-two patients with hospital-acquired pneumonia and 14 with ventilator-associated pneumonia.

^f^Six patients with augmented renal clearance.

The etiology of infection and antimicrobial susceptibility pattern of ESBL-E isolates are reported in [Table 2](#T2){ref-type="table"}. *Escherichia coli* was the most frequently isolated pathogen (48.3%), followed by *Klebsiella pneumoniae* (29.4%) and *Enterobacter* spp. (14.4%).

###### 

Etiology of Infection and Antimicrobial Susceptibility Pattern of ESBL-Producing *Enterobacterales* Isolates

  Etiology                  n = 153 (%)
  ------------------------- --------------------------------
  *Escherichia coli*        74 (48.3)
  *Klebsiella pneumoniae*   45 (29.4)
  *Enterobacter* spp.       22 (14.4)
  *Serratia marcescens*     5 (3.3)
  *Proteus* spp.            3 (2)
  *Citrobacter* spp.        2 (1.3)
  *Morganella morganii*     2 (1.3)
  Antimicrobial Agent       No. of Susceptible Strains (%)
  Amikacin                  128 (83.6)
  Ceftolozane/tazobactam    153 (100)
  Ciprofloxacin             74 (48.3)
  Colistin                  145 (94.7)
  Gentamicin                119 (77.7)
  Fosfomycin                132 (86.2)
  Levofloxacin              88 (57.5)
  Meropenem                 153 (100)
  Piperacillin/tazobactam   104 (67.9)
  Imipenem/cilastatin       153 (100)

Abbreviation: ESBL, extended-spectrum β-lactamase.

At the time of infection, 42 (27.5%) patients presented with septic shock and 91 (59.4%) patients were classified as having a life-threating infection. Overall, source control of infection was considered necessary in 57 patients (37.2%), and in 47/57 cases (82.4%) it was considered adequate.

In most patients, C/T was administered once in vitro susceptibility was confirmed (70%, 107/153), and the median time from infection onset to C/T administration (IQR) was 6 (3--15) days; C/T doses were 1.5 g q8h (or adjusted according to creatinine clearance) in 115 patients (75%) and 3 g q8h in 38 patients (25%). Eighty-three percent of the patients received C/T as monotherapy in definitive therapy; in 26 (16.9%) patients, it was used as combination definitive therapy. No statistically significant differences were reported in the use of C/T in mono or combo definitive therapy with regards to clinical failure (*P* = .34). Overall, C/T was administered for a median duration (IQR) of 14 (8--25) days.

When used as second-line or later, the most common reasons for discontinuation of previous antibiotics were in vitro resistance of strains (69.1%) and clinical failure of previous therapy (30.9%). Piperacillin-tazobactam was the first-line therapy in 35% of patients, followed by cephalosporins (44%) and quinolones (12%). The median follow-up period of the study population (IQR) was 19 (6--49) days.

Overall, 128 (83.6%) patients experienced a successful clinical outcome. Clinical failure was reported in 25 patients: Lack of clinical response was recorded in 4 (16%) patients, recurrence of ESBL-E infection in 6 (24%), and attributable mortality in 15 (60%). [Figure 1](#F1){ref-type="fig"} stratifies the clinical outcome of patients treated with C/T according to the site of infections. Clinical success was observed in 88.3% of patients with cUTI, 88% with ABSSSI, 87.5% with primary bacteremia, 80% with cIAI and bone infections, and 78.3% with hospital-acquired pneumonia. Among 54 (35.2%) patients treated with piperacillin-tazobactam as first-line therapy, clinical failure was reported in 11 patients: 5 patients died, and 6 patients showed lack of clinical response. According to etiology, a successful clinical outcome was reported in 67/74 (90.5%) cases of *Escherichia coli*, 38/45 (84.4%) of *Klebsiella pneumoniae*, and 15/22 (68.2%) of *Enterobacter* spp. infections. All baseline strains showed susceptibility to C/T and carbapenems, whereas only 104 (67.9%) showed susceptibility to piperacillin/tazobactam. Despite this, C/T resistance developed during C/T therapy in 3 patients (1.9%), none of whom had a fatal outcome: 1 patient with HAP (duration of C/T therapy 14 days), 1 patient with primary bacteremia (duration of C/T therapy 15 days), and 1 patient with cIAI (duration of C/T therapy 20 days). All these patients were treated with a standard C/T dosage, with etiology of infection due to *Klebsiella pneumoniae*. The MIC value pretreatment with C/T was ≤1 µg/mL; postexposure it was \>32 µg/mL in 2 patients and \>8 µg/mL in 1 patient. Of 6 (3.9%) patients with augmented renal clearance, clinical failure was recorded in 2 cases (33.3%).

![Comparison of successful clinical outcome in patients receiving ceftolozane/tazobactam in different sites of infection. Abbreviations: ABSSSI, acute bacterial skin and skin-structure infection; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection.](ofaa139f0001){#F1}

Comparison of successful clinical outcome in patients receiving C/T as empiric therapy in comparison with those who received C/T as targeted or rescue therapy is reported in [Figure 2](#F2){ref-type="fig"}. Clinical success was reported in 100% (46/46 cases) of patients treated with empiric therapy, compared with 83.8% (68/86 cases) of targeted therapy and 66.7% (14/21 cases) of rescue therapy (*P* \< .0001) cases.

![Comparison of successful clinical outcome in patients receiving ceftolozane/tazobactam (C/T) as empiric therapy in comparison with those who received C/T as targeted or rescue therapy.](ofaa139f0002){#F2}

In [Table 3](#T3){ref-type="table"} is reported univariate analysis of risk factors associated with clinical failure of C/T therapy. ICU hospitalization at the time of infection (40% vs 15.6%; *P* = .01), higher mean Charlson comorbidity index (5.4 points vs 3.6 points; *P* \< .001), chronic renal disease (60% vs 28.1%; *P* \< .001), need for mechanical ventilation or noninvasive ventilation (40% vs 14%; *P* = .004), CRRT (40% vs 6.2%; *P* \< .001), and septic shock (80% vs 17.2%; *P* \< .001) were associated with clinical failure of C/T therapy. Conversely, receipt of C/T as empiric therapy (35.9% vs 0%; *P* \< .001) and adequate source control of infection (75.4% vs 7.1%; *P* \< .001) were associated with clinical success of C/T therapy. A lower time from infection onset to C/T administration was reported in patients with clinical success (4 vs 7 days; *P* \< .001). [Table 4](#T4){ref-type="table"} shows descriptions of patients who experienced clinical failure with C/T therapy.

###### 

Univariate Analysis of Risk Factors for Clinical Failure of C/T Therapy Among Patients With Enterobacterales Infection

  Variable                                                              Clinical Success (n = 128), No. (%)^a^   Clinical Failure (n = 25), No. (%)^a^   *P* Value
  --------------------------------------------------------------------- ---------------------------------------- --------------------------------------- -----------
  Age, median (IQR), y                                                  69 (48--78)                              68 (47--77)                             .92
  Male sex                                                              69 (53.9)                                13 (52)                                 1.0
  Community-acquired infection                                          9 (7)                                    1 (4)                                   .78
  Hospital-acquired infection                                           119 (92.9)                               24 (96)                                 .89
  Ward                                                                                                                                                   
   Medical                                                              85 (66.4)                                13 (52)                                 .17
   Surgical                                                             23 (17.9)                                2 (8)                                   .37
   ICU                                                                  20 (15.6)                                10 (40)                                 .01
   Charlson comorbidity index, mean ± SD                                3.6 ± 3                                  5.4 ± 2.6                               \<.001
  Underlying diseases                                                                                                                                    
   Cardiac disease                                                      46 (35.9)                                10 (40)                                 .82
   Neurological disease                                                 46 (35.9)                                7 (28)                                  .49
   Chronic renal disease                                                36 (28.1)                                15 (60)                                 \<.001
   Diabetes mellitus                                                    35 (27.3)                                7 (28)                                  1.0
   Gastrointestinal disease                                             35 (27.3)                                6 (24)                                  .8
   Solid-organ tumor                                                    28 (21.8)                                9 (36)                                  .19
   Solid-organ transplant                                               14 (10.9)                                5 (20)                                  .2
   Hematological malignancy                                             15 (11.7)                                5 (20)                                  .28
   COPD                                                                 29 (22.6)                                6 (24)                                  1.0
   Liver disease                                                        18 (14)                                  4 (16)                                  .92
  Other predisposing conditions^b^                                                                                                                       
   Corticosteroids                                                      45 (35.1)                                7 (28)                                  .64
   Other immunosuppressive therapy                                      23 (17.9)                                6 (24)                                  .57
   Chemotherapy                                                         14 (10.9)                                3 (12)                                  1.0
   Neutropenia^c^                                                       14 (10.9)                                1 (4)                                   .46
  Invasive procedures                                                                                                                                    
   Central venous catheter                                              58 (45.3)                                18 (72)                                 .01
   Urinary catheter                                                     91 (71.1)                                20 (80)                                 .46
   Previous surgery^b^                                                  48 (37.5)                                10 (40)                                 .82
   Mechanical ventilation/NIV                                           18 (14)                                  10 (40)                                 .004
   Percutaneous endoscopic gastrostomy                                  2 (1.5)                                  0                                       1.0
   Intermittent hemodialysis                                            17 (13.2)                                8 (32)                                  .03
   CRRT                                                                 8 (6.2)                                  10 (40)                                 \<.001
   Previous ESBL-E colonization^b^                                      40 (31.2)                                10 (40)                                 .48
  Severity of clinical presentation                                                                                                                      
   No sepsis                                                            52 (40.6)                                0                                       \<.001
   Sepsis                                                               54 (42.2)                                5 (20)                                  .04
   Septic shock                                                         22 (17.2)                                20 (80)                                 \<.001
   ICU admission due to ESBL-E infection                                62 (48.4)                                12 (48)                                 1.0
  Type of infection                                                                                                                                      
   Nosocomial pneumonia^e^                                              33 (25.7)                                13 (25)                                 1.0
   ABSSSI                                                               25 (19.5)                                0                                       .01
   cUTI                                                                 31 (24.2)                                3 (12)                                  .29
   cIAI                                                                 19 (14.8)                                6 (24)                                  .24
   Bone infection                                                       4 (3.1)                                  1 (4)                                   1.0
   Primary bacteremia                                                   14 (10.9)                                2 (8)                                   1.0
   Other infections^d^                                                  2 (1.5)                                  0                                       1.0
  Concomitant ESBL-E bacteremia                                         35 (27.3)                                12 (48)                                 .05
  Life-threatening infection                                            81 (63.2)                                10 (40)                                 .04
  Polymicrobial infection                                               24 (18.7)                                7 (28)                                  .28
  Antibiotics before C/T treatment                                                                                                                       
   Received antibiotics before C/T for current infection                35 (27.3)                                17 (68)                                 \<.001
   No. of antibiotics received, median (range)                          1 (1--3)                                 2 (1--4)                                .08
   Days of antibiotic therapy, median (range)                           6 (3--13)                                7 (4--15)                               .07
  C/T treatment                                                                                                                                          
   Empiric treatment                                                    46 (35.9)                                0                                       \<.001
   Combination therapy                                                  23 (17.9)                                3 (12)                                  .57
   Time from infection onset to C/T administration, median (IQR), d     4 (1--6)                                 7 (5--14)                               \<.001
   Days of treatment, median (range)                                    11 (6--22)                               17 (7--29)                              \<.001
   Extended infusion                                                    32 (25)                                  2 (8)                                   .06
   Continuous infusion                                                  9 (7)                                    2 (8)                                   1.0
   Intermittent infusion                                                87 (67.9)                                21 (84)                                 .14
   Standard dosage (or adjusted according to creatinine clearance)^f^   95 (74.2)                                20 (80)                                 .62
   Off-label dosage                                                     33 (25.7)                                5 (20)                                  .68
  Adequate source control of infection                                  43/57 (75.4)                             4/57 (7.1)                              \<.001

Abbreviations: ABSSSI, acute bacterial skin and skin-structure infection; C/T, ceftolozane/tazobactam; cIAI, complicated intra-abdominal infection; COPD, chronic obstructive pulmonary disease; CRRT, continuous renal replacement therapy; cUTI, complicated urinary tract infection; ESBL-E, extended-spectrum β-lactamase *Enterobacterales*; ICU, intensive care unit; IQR, interquartile range; NIV, noninvasive ventilation.

^a^Data are No. (%) unless otherwise stated.

^b^Within previous 30 days.

^c^Absolute neutrophil count \<500/mm^3^.

^d^Other infections include central venous catheter--related bacteremia (n = 1) and community-acquired pneumonia (n = 1).

^e^Nosocomial pneumonia was divided into 26 patients with hospital-acquired pneumonia and 7 with ventilator-associated pneumonia among patients with clinical success; 6 patients with hospital-acquired pneumonia and 7 with ventilator-associated pneumonia among patients with clinical failure.

^f^Augmented renal clearance was reported in 4 patients with clinical success and 2 patients with clinical failure.

###### 

Description of Patients Who Experienced Clinical Failure With Ceftolozane/Tazobactam Therapy

  Case   Type of Infection    Concomitant BSI   Therapy Before C/T           Dose of C/T for the Present Infection                             Concomitant Isolates                          Additional Information                                                     Reason for Clinical Failure
  ------ -------------------- ----------------- ---------------------------- ----------------------------------------------------------------- --------------------------------------------- -------------------------------------------------------------------------- -----------------------------
  1      HAP                  Yes               Cefepime                     Off-label dosage                                                  No                                            Septic shock, CRRT                                                         Died
  2      HAP                  Yes               Piperacillin/tazobactam      Standard dosage (or adjusted according to creatinine clearance)   *Acinetobacter baumannii*                     Septic shock                                                               Died
  3      HAP                  Yes               Piperacillin/tazobactam      Standard dosage (or adjusted according to creatinine clearance)   *Acinetobacter baumannii*                     Septic shock, CRRT                                                         Lack of clinical response
  4      HAP                  Yes               Piperacillin/tazobactam      Standard dosage (or adjusted according to creatinine clearance)   No                                            Septic shock                                                               Died
  5      HAP                  Yes               Piperacillin/tazobactam      Off-label dosage                                                  No                                            Septic shock                                                               Lack of clinical response
  6      HAP                  Yes               Piperacillin/tazobactam      Standard dosage (or adjusted according to creatinine clearance)   No                                            CRRT                                                                       Lack of clinical response
  7      VAP                  Yes               Piperacillin/tazobactam      Off-label dosage                                                  No                                            Septic shock                                                               Died
  8      VAP                  Yes               Piperacillin/tazobactam      Off-label dosage                                                  No                                            Septic shock                                                               Lack of clinical response
  9      VAP                  Yes               Meropenem                    Off-label dosage                                                  No                                            CRRT                                                                       Lack of clinical response
  10     VAP                  Yes               Meropenem                    Standard dosage (or adjusted according to creatinine clearance)   No                                            Septic shock                                                               Died
  11     VAP                  No                Meropenem                    Standard dosage (or adjusted according to creatinine clearance)   *Acinetobacter baumannii*                     Septic shock, CRRT                                                         Died
  12     VAP                  No                Meropenem                    Standard dosage (or adjusted according to creatinine clearance)   No                                            Septic shock                                                               Died
  13     VAP                  No                Cefepime                     Standard dosage (or adjusted according to creatinine clearance)   No                                            Septic shock                                                               Died
  14     cUTI                 No                Piperacillin/tazobactam      Standard dosage (or adjusted according to creatinine clearance)   No                                            Inadequate source control of infection, septic shock, CRRT                 Died
  15     cUTI                 No                Piperacillin/tazobactam      Standard dosage (or adjusted according to creatinine clearance)   No                                            Inadequate source control of infection, septic shock, CRRT                 Died
  16     cUTI                 No                Piperacillin/tazobactam      Standard dosage (or adjusted according to creatinine clearance)   No                                            Inadequate source control of infection, septic shock                       Lack of clinical response
  17     cIAI                 Yes               Ceftriaxone+metronidazole    Augmented renal clearance                                         *Acinetobacter baumannii*                     Inadequate source control of infection                                     Lack of clinical response
  18     cIAI                 Yes               Levofloxacin+metronidazole   Standard dosage (or adjusted according to creatinine clearance)   *Enterococcus faecium* vancomycin-resistant   Inadequate source control of infection, inadequate antimicrobial therapy   Lack of clinical response
  19     cIAI                 No                Piperacillin/tazobactam      Standard dosage (or adjusted according to creatinine clearance)   No                                            Inadequate source control of infection, septic shock                       Lack of clinical response
  20     cIAI                 No                Ceftriaxone+metronidazole    Standard dosage (or adjusted according to creatinine clearance)   No                                            Inadequate source control of infection, septic shock, CRRT                 Died
  21     cIAI                 No                Ceftriaxone+metronidazole    Standard dosage (or adjusted according to creatinine clearance)   No                                            Inadequate source control of infection, CRRT                               Died
  22     cIAI                 No                Cefepime+metronidazole       Standard dosage (or adjusted according to creatinine clearance)   No                                            Inadequate source control of infection, septic shock, CRRT                 Died
  23     Bone infection       No                Cefepime+levofloxacin        Standard dosage (or adjusted according to creatinine clearance)   No                                            Inadequate source control of infection, septic shock                       Lack of clinical response
  24     Primary bacteremia   \-                Cefepime                     Standard dosage (or adjusted according to creatinine clearance)   MRSA                                          Septic shock                                                               Died
  25     Primary bacteremia   \-                Ceftriaxone                  Augmented renal clearance                                         MRSA                                          Septic shock                                                               Died

Abbreviations: CRRT, continuous renal replacement therapy; HAP, hospital-acquired pneumonia; IAI, intra-abdominal infection; MRSA, methicillin-resistant *Staphylococcus aureus*; UTI, urinary tract infection; VAP, ventilator-associated pneumonia.

Finally, in multivariate analysis, Charlson comorbidity index \>4 (odds ratio \[OR\], 2.3; 95% confidence interval \[CI\], 1.9--3.5; *P* = .02), septic shock (OR, 6.2; 95% CI, 3.8--7.9; *P* \< .001), and continuous renal replacement therapy (OR, 3.1; 95% CI, 1.9--5.3; *P* = .001) were independently associated with clinical failure, whereas empiric therapy displaying in vitro activity (OR, 0.12; 95% CI, 0.01--0.34; *P* \< .001) and adequate source control of infection (OR, 0.42; 95% CI, 0.14--0.55; *P* \< .001) were associated with clinical success ([Table 5](#T5){ref-type="table"}).

###### 

Multivariate Analysis of Risk Factors for Clinical Failure of C/T Therapy Among Patients With Enterobacterales Infection

  Variable                                       OR     95% CI       *P* Value
  ---------------------------------------------- ------ ------------ -----------
  Charlson comorbidity index \>4                 2.3    1.9--3.5     .02
  Septic shock                                   6.2    3.8--7.9     \<.001
  Empiric therapy displaying in vitro activity   0.12   0.01-0-34    \<.001
  CRRT                                           3.1    1.9--5.3     .001
  Adequate source control of the infection       0.42   0.14--0.55   \<.001

Abbreviations: C/T, ceftolozane/tazobactam; CI, confidence interval; CRRT, continuous renal replacement therapy; OR, odds ratio.

DISCUSSION {#s10}
==========

This study reports the largest clinical experience with C/T therapy for the treatment of serious ESBL-E infection published so far. We showed that C/T is an effective drug for treating different types of ESBL-E infections. This analysis also indicated that baseline conditions (expressed by a higher Charlson comorbidity index score), severity of clinical presentation at the time of infection (as demonstrated by the percentage of septic patients in the study population), and CRRT are associated with a significantly increased risk of clinical failure, whereas empiric therapy displaying in vitro activity and adequate source control of infection are associated with clinical success. Of importance, clinical success was observed in 83.7% of patients; over 65% of patients developed sepsis (38.6%) or septic shock (27.5%) at the time of infection.

As previously reported in the literature \[[@CIT0001]\], severe infections caused by ESBL-E are associated with high rates of treatment failure and increased mortality, particularly when appropriate antimicrobial therapy is delayed. The role of carbapenems, considered the first choice for the treatment of these infections \[[@CIT0020], [@CIT0021]\], was redefined also for the high incidence of carbapenem-resistant *Enterobacterales* strains observed in the last few years. Attention is now focused on promotion of carbapenem-sparing strategies and evaluation of the efficacy of other drugs, like BLBLI combinations that remain active against a considerable proportion of ESBL-E; however, the role of these drugs is controversial for the treatment of serious infections due to ESBL pathogens \[[@CIT0022], [@CIT0023]\].

In a pooled post hoc analysis including patients from both ASPECT-cIAI \[[@CIT0008]\] and ASPECT-cUTI \[[@CIT0007]\] who had an ESBL-E in their baseline cultures (150/1346, 11.1%), clinical cure rates were 97.4% for C/T (76/78), 82.6% for levofloxacin, and 88.5% for meropenem (23/26) \[[@CIT0024]\]. Interestingly, in our population a high clinical success rate was also retained in patients who received C/T as salvage therapy (76.2%), as well as those with life-threatening infection (63.2%). Our data are in line with those of the recently published paper ASPECT-NP \[[@CIT0014]\], studying patients with severe intubated pneumonia, which demonstrated a microbiological success rate in infections caused by ESBL-E of 57% for C/T compared with 61.6% for meropenem in a setting of ESBL-E resistant to C/T, for a rate of 38%. This study caused EUCAST to increase the breakpoints of C/T from 1 mg/L to 2 mg/L \[[@CIT0025]\].

These clinical data, in line with the high in vitro activity against ESBL producers reported in the literature \[[@CIT0005]\], configure for C/T a possible role (also in empiric therapy) as a carbapenem-sparing agent, especially in a geographical area with high spread of gram-negative carbapenem-resistant strains \[[@CIT0006]\] and in patients with a lower risk of infection caused by a carbapenem-resistant strain \[[@CIT0026]\]. Of importance, no clinical failure was reported among patients with C/T administered in empiric therapy when compared with patients for whom C/T was used in targeted or rescue therapy (*P* \< .001). This observation is in line with our data from multivariate analysis, which showed that as empiric therapy, C/T displayed in vitro activity associated with clinical success in this study population. Of interest, according to etiology, a successful clinical outcome was reported in a high percentage (90.5%) of cases with *Escherichia coli* infections, while a lower rate of clinical success was observed for those with *Klebsiella pneumoniae* (84.4%) and *Enterobacter* spp. infections (68.2%), in line with previous observations \[[@CIT0024]\].

On this basis, reflecting an unmet need for licensed treatment options, C/T is frequently used for off-label indications, and data regarding how C/T performs overall in the treatment of severe infections are expanding \[[@CIT0011]\]. Recently, a randomized, controlled, double-blind, phase 3 noninferiority trial (ASPECT-NP) compared C/T (3 g every 8 hours) with meropenem for treatment of nosocomial pneumonia. Of importance, high-dose C/T was efficacious and well tolerated for gram-negative nosocomial pneumonia in this critically ill population, comprising mechanically ventilated patients \[[@CIT0014]\].

The current study confirms a previous observation on an association between clinical failure and receipt of CRRT during C/T therapy \[[@CIT0012]\]. Optimal dosing of C/T in patients receiving CRRT is an unresolved issue, and no dosing recommendations are currently available in this specific setting \[[@CIT0006]\]. Previous preliminary reports \[[@CIT0016],[@CIT0017]\] have suggested that a standard dosage of 1.5 g q8h should ensure appropriate C/T exposure for the treatment of pneumonia in patients undergoing CRRT. However, considering that all patients with CRRT in the current study received a C/T dosage of 1.5 g q8h, we suggest consideration of an increased posology of C/T in these patients or, if possible, routine performance of therapeutic drug monitoring.

Finally, no differences in clinical response rates between patients treated with combination therapy and those treated with monotherapy were observed in this study (*P* = .34). However, the low number of patients receiving combination therapy (n = 26) prevents us from drawing further conclusions with regard to the benefit of combination treatment, especially in patients with high risk of mortality such as those presenting with septic shock. Moreover, another interesting finding was the low number of observed AEs during treatment. Only 2 patients developed mild AEs, although threating physicians interrupted treatment in both patients. In pivotal clinical trials, gastrointestinal side effects and abnormal liver enzyme increase were also the most frequent AEs described \[[@CIT0007], [@CIT0008]\].

This study has several limitations that should be addressed. First, it was an observational, retrospective study; therefore, we may not have been able to control for all measured and unmeasured variables that may have had a clinical impact on patient evolution. Nevertheless, our series of ESBL-E infections treated with C/T is the largest real-life experience ever reported in literature. Second, C/T was mainly administered as second- or third-line therapy, and the role of prior therapy on clinical outcome is unclear. Third, susceptibility testing was performed at each individual center, and we do not have molecular analysis to determine the presence of enzymes associated with antibiotic resistance in the isolates. Fourth, we did not perform antibiotic blood levels, and we cannot exclude that clinical failure in some critically ill patients could be related to the higher clearance of β-lactams \[[@CIT0027]\], considering also lack of information about other variables that may influence the outcome, such as circulatory management. Finally, no data were recorded on long-term survival over 30 days; thus, we cannot provide more consistent information on the risk of recurrence of infection and emergence of strains resistant to C/T therapy.

In conclusion, our data showed that C/T could be a valid option in empiric and/or targeted therapy in patients with severe infections caused by ESBL-producing *Enterobacterales*. The decision about C/T in empiric therapy was based on clinical judgment at participating centers. In our opinion, the reason for the use of C/T was based on knowledge of high spread of ESBL strains in the geographical area involved in this study, the high rate of hospital-acquired infection, and the severity of the clinical condition (as expressed by Charlson comorbidity index score and/or rate of septic shock). Clinicians should be aware of the risk of clinical failure with C/T therapy in septic patients receiving CRRT. The results of this study are relevant to physicians who attend patients with a wide variety of diseases and severity of illness.
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